Literatur
- 1
Bechrakis N E, Anastassiou G, Bornfeld N. et al .
Okuläre Melanome – Klinik und Lokaltherapie.
Der Onkologe.
2006;
12
213-221
- 2
Daniell M, Maini R, Tole D.
Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplaisa.
Clin Experiment Ophthalmol.
2002;
30
94-98
- 3 De Wolff-Rouendaal D. Melanozytäre Tumoren der Bindehaut. Lommatzsch PK Ophthalmologische
Onkologie Stuttgart; Enke 1999: 81-95
- 4
Demirci H, McCormick S, Finger P.
Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired
melanosis with atypia: clinical experience with histopathologic observations.
Arch Ophthalmol.
2000;
118
885-891
- 5
Dudney B W, Malecha M A.
Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal
intraepithelial neoplasia.
Am J Ophthalmol.
2004;
137
950-951
- 6
Finger P T, Grazyna C, Liarikos S.
Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia.
Br J Ophthalmol.
1998;
82
476-479
- 7
Frucht-Pery J. et al .
Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia. A multicenter
experience.
Ophthalmology.
1997;
104
2085-2093
- 8
Frucht-Pery J, Rozenman Y.
Mitomycin C therapy for corneal intraepithelial neoplasia.
Am J Ophthalmol.
1994;
117
164-168
- 9
Heigle T J, Stulting R D, Palay D A.
Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin C.
Am J Ophthalmol.
1997;
124
397-399
- 10
Khong J J, Muecke J.
Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasie.
Br J Ophthalmol.
2006;
90
819-822
- 11
Löffler K U.
Mitomycin als Lokaltherapeutikum bei okulären Neoplasien.
Der Ophthalmologe.
1997;
94
529-531
- 12
Lommatzsch P K, Werschnik C.
Malignant Conjunctival Melanoma. Clinical Review with Recommendations for Diagnosis,
Therapy and Follow-up.
Klin Monatsbl Augenheilkd.
2002;
219
710-721
- 13 Manual Maligne Melanome – Empfehlungen zur Diagnostik, Therapie und Nachsorge. München;
Zuckschwerdt Verlag 2000: 106-109
- 14
Paridaens A DA, Minassian D C, McCartney A CE. et al .
Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological
study of 256 Cases.
Br J ophthalmol.
1994;
78
252-259
- 15
Sacu S. et al .
Intumescent cataract after topical mitomycin C for conjunctival malignant melanoma.
Am J Ophthalmol.
2003;
136
375-377
- 16
Seregard S, Kock E.
Conjunctival malignant melanoma in Sweden 1969 – 91.
Acta Ophthalmol.
1992;
70
289-296
- 17
Shields C L. et al .
Conjunctival Melanoma-Risk Factors for Recurrence, Exenteration, Metastasis, and Death
in 150 Consecutive Patients.
Arch Ophthalmol.
2000;
118
1497-1507
- 18
Shields C L, Naseripour M, Shields J A.
Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland
carcinoma.
Ophthalmology.
2002;
109
2129-2133
- 19
Shields C L, Naseripour M, Shields J A.
Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma.
Am J Ophthalmol.
2002;
133
601-606
- 20
Shields C L, Shields J A.
Tumors of the conjunctiva and cornea.
Surv Ophthalmol.
2004;
49
3-24
- 21
Werschnik C, Lommatzsch P K.
Long-Term Follow-up of Patients With Conjunctival Melanoma.
Am J Clin Oncol.
2002;
25
248-255
- 22
Wilson M W. et al .
Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia
and neoplasia.
Am J Ophthalmol.
1997;
124
303-311
Dr. Anne Hoyer
Augenklinik, Universitätsklinikum C. G. Carus Dresden
Fetscher Str. 74
01307 Dresden
Phone: ++ 49/3 51/4 58 33 81
Fax: ++ 49/3 51/4 58 43 35
Email: anne.hoyer@uniklinikum-dresden.de
